-transparent.png){kind=logo}
The interaction between the histamine H-2 receptor antagonist, cimetidine, and warfarin sodium was prospectively studied in 14 patients who were previously anticoagulated for five years. The patients received warfarin and cimetidine concomitantly for a minimum of ten days. Seven of the patients experienced increases in plasma warfarin concentrations. This correspondingly resulted in abnormal prolongation of their prothrombin times. In these patients the elevation in the steady-state warfarin concentration demonstrates that coadministration of cimetidine significantly reduces the plasma clearance rate of warfarin. The serum and urine metabolite levels of warfarin were not qualitatively different in the absence in contrast to the presence of cimetidine. It is apparent that cimetidine can act as an inhibitory influence on the catabolic degradation of warfarin.
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
January 1983,
European journal of clinical pharmacology,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
March 1984,
Clinical pharmacology and therapeutics,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
December 1985,
British journal of clinical pharmacology,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
September 1982,
Die Medizinische Welt,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
February 1979,
The Medical journal of Australia,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
February 1986,
Journal of pharmaceutical sciences,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
January 1998,
Pediatric nephrology (Berlin, Germany),
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
April 1985,
Clinical pharmacology and therapeutics,
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
September 1979,
Lancet (London, England),
W R Bell, and
K C Anderson, and
D A Noe, and
B A Silver
April 1996,
Clinical pharmacology and therapeutics,
